Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States

Journal of the American College of Cardiology

Volumn 73, Issue 9, 2019, Pages 1101-1103

  Greene, Stephen J ^a   Wilson, Lauren E ^a   Abbasi, Siddique A ^a   Yusuf, Akeem A ^a   Hammill, Bradley G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT;

ALL CAUSE MORTALITY; DIURETIC THERAPY; EMERGENCY CARE; HEART FAILURE; HOSPITAL READMISSION; HUMAN; LETTER; OUTPATIENT CARE; PRIORITY JOURNAL; INTRAVENOUS DRUG ADMINISTRATION; OUTPATIENT; UNITED STATES;

DIURETICS; HEART FAILURE; HUMANS; INJECTIONS, INTRAVENOUS; OUTPATIENTS; UNITED STATES;

EID: 85062012939     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.12.034     Document Type: Letter

References (3)

1. Greene, S.J., Mentz, R.J., Felker, G.M., Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol 3 (2018), 252–259.
2. Hicks, K.A., Mahaffey, K.W., Mehran, R., et al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol 71 (2018), 1021–1034.
3. Gheorghiade, M., Greene, S.J., Butler, J., et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA 314 (2015), 2251–2262.